Delstrigo Europäische Union - Deutsch - EMA (European Medicines Agency)

delstrigo

merck sharp & dohme b.v. - doravirine, lamivudin, tenofovir disoproxil fumarate - hiv-infektionen - antivirale mittel zur behandlung von hiv-infektionen, kombinationen - delstrigo ist indiziert für die behandlung von erwachsenen mit hiv infiziert 1 ohne vergangenheit oder gegenwart beweise des widerstands gegen die nnrti-klasse, lamivudin oder tenofovir. delstrigo is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg who are infected with hiv-1 without past or present evidence of resistance to the nnrti class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.

Rukobia 600 mg Retardtabletten Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

rukobia 600 mg retardtabletten

viiv healthcare gmbh - fostemsavirum - retardtabletten - fostemsavirum 600 mg ut fostemsavirum trometamolum, hydroxypropylcellulosum, hypromellosum, silica colloidalis anhydrica, magnesii stearas, poly(alcohol vinylicus) e 171 macrogolum 3350 talcum e 172 (flavum) e 172 (rubrum), pro compresso obducto. - hiv-infektion - synthetika

Tavneos Europäische Union - Deutsch - EMA (European Medicines Agency)

tavneos

vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - immunsuppressiva - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).

Tavneos 10 mg Hartkapseln Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

tavneos 10 mg hartkapseln

vifor fresenius medical care renal pharma ltd. - avacopanum - hartkapseln - avacopanum 10 mg, macrogolglyceroli hydroxystearas 245 mg, macrogolum 4000, kapselhülle: e 172 (rubrum), e 172 (flavum), e 171, gelatina, polysorbatum 80, drucktinte: e 172 (nigrum), pro capsula. - behandlung erwachsener patienten mit schwerer aktiver vaskulitis (granulomatose mit polyangiitis (gpa) oder mikroskopischer polyangiitis (mpa)) - synthetika

Lumykras Europäische Union - Deutsch - EMA (European Medicines Agency)

lumykras

amgen europe bv - sotorasib - karzinom, nicht kleinzellige lunge - antineoplastische mittel - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.